OPKO Health to sell oncology testing assets to Labcorp for up to $225M

OPKO HEALTH, INC.

Purchase price: $192.5M at closing plus up to $32.5M in earnout based on performance.
Divested assets generate ~$85-100M in annual revenue; deal expected to close H2 2025.
BioReference retains core NY/NJ clinical testing and 4Kscore franchise (~$300M 2024 revenue).
Labcorp expects acquisition to be accretive to earnings in year one.
Transaction includes customary closing conditions and state regulatory approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.